Centro de Terapia Celular (CTC)

• Processo: 10/16647-5
• Modalidade de apoio: Bolsas no Brasil - Programa Capacitação - Treinamento Técnico
• Data de Início da vigência: 01 de novembro de 2010
• Data de Término da vigência: 31 de dezembro de 2011
• Área de conhecimento: Ciências da Saúde - Medicina - Clínica Médica
• Pesquisador responsável: Eduardo Magalhães Rego
• Beneficiário: Lisandra Moreira de Oliveira
• Instituição Sede: Hemocentro de Ribeirão Preto. Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP (HCMRP). Secretaria da Saúde (São Paulo - Estado). Ribeirão Preto , SP, Brasil
• Vinculado ao auxílio: 98/14247-6 - Center for Research on Cell-Based Therapy, AP.CEPID
• Assunto(s): Modelos animais Terapia baseada em transplante de células e tecidos Hematologia
• Palavra(s)-Chave do Pesquisador: leucemias agudas | modelos animais | terapia celular | Hematologia

Resumo

The CTC was originally based on the broad concept of using cells for therapy, under different conditions and from several sources. Thanks to the input of the reviewers and to the achievements of the research program, our activities are now more focused and the efforts of the principal investigators are more interrelated and coordinated in four areas: a. Characteristics and manipulation of the cells used for therapy, b. Characteristics of the recipients, affected with neoplastic blood diseases, c. Relationship of the host with parasites transmitted by cell therapy, d. Transgenic animals as experimental models. The present application for a TT3 fellowship is related to the study of the molecular basis of leukemogenesis using the acute promyelocytic leukemia as a model. The transgenic mice (TM)we have been analyzing express PML/RARalpha under the control of human cathepsin G promotor and, develop a form of leukemia that mimics the hematological findings of human APL. Leukemia is diagnosed after a long latency (approximately 12 months) during which no hematological abnormality is detected in peripheral blood (pre-leukemic phase). Our proposal aim to indentify other genetic lesions that may act facilitating leukemogenesis.